Rallybio Corporation RLYB NASDAQ · Healthcare · United States
$15.72 +0.45% +$0.07
Summary
53 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 6,177 USD is left as net profit.
- It has no debt and holds $90.7M in cash.
- You pay 3.1 USD for 1 USD of yearly profit, little for its sector.
What to watch
- It pays out more in dividends than it earns: 272% of profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapToday you pay 3.1 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
There is not enough revenue history yet to say how fast it grows.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 843 USD
- Research and development 1,167 USD
- Sales and administration 2,749 USD
- Taxes and other -10,837 USD
- Net profit 6,177 USD
Net profit, industry median (Biotechnology) -11 USD
Out of every 100 USD of revenue, 6,177 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt has no debt.
Financial health in detailDoes it pay a dividend?
High, at risk- Yield
- 86.65%
- Paid out of profit
- 272%
You receive 13.56 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Neutral- Buy 4
- Hold 5
- Sell 0
No analyst has published a price target.
44% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Collaboration And License Revenue 52%
- License 48%
By region
The company reports no revenue by region.
Collaboration And License Revenue brings in 52% of revenue.
Segments in detail